Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 819
interventional 684
Observational 122
Registry 13

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 258
Drug|placebo 169
Dietary Supplement 50
Dietary Supplement|placebo 44
Behavioral 43
Other 39
Biological 13
Procedure 9
Biological|placebo 7
Device 7
Drug|Other|placebo 5
Behavioral|Drug 4
Drug|Procedure 4
Genetic 4
Biological|Drug|placebo 3
Dietary Supplement|Other 3
Dietary Supplement|Drug|placebo 2
Behavioral|Device 1
Behavioral|Dietary Supplement 1
Behavioral|Dietary Supplement|Drug 1
Behavioral|Drug|placebo 1
Behavioral|placebo 1
Biological|Drug|Other|placebo 1
Biological|Other 1
Biological|Procedure 1
Combination Product|Drug|placebo 1
Device|Drug 1
Device|Other|Procedure 1
Device|Procedure 1
Dietary Supplement|Drug 1
Dietary Supplement|Drug|Other 1
Dietary Supplement|Other|placebo 1
Drug|Genetic 1
Drug|Other 1
Other|placebo 1
placebo 1
Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
NA 169
United States 158
Canada 31
Korea, Republic of 25
China 21
Germany 21
Japan 21
United States|Canada 15
United Kingdom 14
France 13
Italy 11
Netherlands 11
Spain 11
Norway 7
Austria 6
Australia 5
Sweden 5
Brazil 4
Denmark 4
Greece 4
Belgium 3
Finland 3
India 3
Taiwan 3
United States|Netherlands 3
Czech Republic 2
Denmark|Germany|Israel|Netherlands|United Kingdom 2
Iran, Islamic Republic of 2
Israel 2
Thailand 2
United States|Australia|Canada 2
United States|Australia|Canada|France|Germany|Italy|Mexico|Spain|United Kingdom 2
United States|Brazil|Canada|Singapore|South Africa|Taiwan|United Kingdom 2
United States|Canada|Germany|Netherlands|United Kingdom 2
United States|Canada|Italy|South Africa 2
Armenia 1
Australia|Canada|United Kingdom 1
Australia|New Zealand 1
Austria|Belgium|Canada|Czechia|Denmark|Finland|France|Germany|Greece|Hungary|Poland|Romania|Slovakia|Slovenia|Spain|Switzerland 1
Belgium|Canada|Denmark|Israel|Malaysia|Netherlands|Taiwan 1
Belgium|Canada|Denmark|Israel|Malaysia|Taiwan 1
Brazil|Canada|Denmark|Mexico|Netherlands|Russian Federation|Slovenia|Spain|Taiwan|Turkey 1
Bulgaria|United States|Chile|Estonia|Japan|Mexico|Russian Federation|South Africa|Ukraine 1
Canada|Czech Republic|France|Poland|Romania|Russian Federation|Slovakia 1
Canada|France|Netherlands|Norway 1
Canada|Greece|Norway 1
Chile 1
Chile|Hungary|Korea, Republic of|Mexico|Russian Federation|Turkey 1
China|Hong Kong|Korea, Republic of|Malaysia|Taiwan|Thailand 1
China|India|Thailand 1
Costa Rica|Croatia|Czech Republic|Dominican Republic|Indonesia|Jordan|Korea, Republic of|Kuwait|Lebanon|Malaysia|Mexico|Panama|Philippines|Russian Federation|Saudi Arabia|Taiwan|Thailand|Turkey|United Arab Emirates|Venezuela 1
Czech Republic|Estonia|Finland|Germany|Poland|South Africa|United Kingdom 1
Czech Republic|Netherlands|Norway|United Kingdom 1
Denmark|Finland|Germany|India|Israel|Italy|Netherlands|Norway|Poland|Russian Federation|Spain|Sweden|United Kingdom 1
Denmark|Finland|Germany|India|Israel|Italy|Netherlands|Norway|Poland|Russian Federation|United Kingdom|Spain|Sweden 1
Denmark|Netherlands|Spain|Sweden 1
Estonia|Latvia|Russian Federation|Serbia 1
France|Belgium|Netherlands 1
France|Germany|Netherlands|Sweden|United Kingdom 1
France|Moldova, Republic of 1
Germany|Switzerland 1
Hong Kong|Israel|Russian Federation|Serbia|South Africa|Taiwan|Turkey|Ukraine 1
Hungary|India|Israel|Italy|United States|Argentina|Australia|Belgium|Brazil|Canada|Croatia|Czechia|Denmark|Germany|Greece|Hong Kong|Korea, Republic of|Malaysia|Netherlands|New Zealand|Norway|Poland|Russian Federation|South Africa|Spain|Sweden|Taiwan|Turkey|Ukraine|United Kingdom 1
Ireland 1
Israel|Italy|Japan|Lebanon|Netherlands|United States|Australia|Belgium|Brazil|Canada|Czechia|France|Greece|Hong Kong|New Zealand|South Africa|Spain|United Kingdom 1
Israel|United States|Australia|Austria|Canada|Netherlands|Norway|South Africa 1
Italy|Finland|Norway|Russian Federation|United Kingdom 1
Korea, Republic of|Taiwan 1
Malaysia 1
Netherlands|Denmark|Spain|Sweden 1
Pakistan 1
Poland|Czechia|Germany|Hungary|South Africa|Ukraine|United Kingdom 1
Singapore 1
Switzerland 1
Turkey 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Chile|Czechia|Denmark|France|Germany|Greece|Hungary|Iceland|Ireland|Israel|Italy|Korea, Republic of|Malaysia|Mexico|Netherlands|Norway|Philippines|Poland|Russian Federation|Singapore|South Africa|Spain|Sweden|Switzerland|Taiwan|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Chile|Czechia|France|Germany|Greece|Hungary|Iceland|Ireland|Israel|Italy|Korea, Republic of|Malaysia|Mexico|Netherlands|Norway|Poland|Russian Federation|South Africa|Spain|Sweden|Switzerland|Taiwan|United Kingdom 1
United States|Argentina|Austria|Belgium|Bulgaria|Canada|Czechia|Denmark|Finland|France|Germany|Hungary|Israel|Italy|Mexico|Netherlands|Norway|Portugal|Romania|Russian Federation|South Africa|Spain|Sweden|United Kingdom 1
United States|Argentina|Austria|Brazil|Bulgaria|Canada|Czechia|Denmark|Finland|France|Hungary|Italy|Lebanon|Mexico|Netherlands|Norway|Poland|Russian Federation|Slovenia|South Africa|Spain|Sweden|Taiwan|Turkey 1
United States|Argentina|Belgium|Bulgaria|Canada|Chile|Colombia|Czech Republic|Denmark|Finland|France|Germany|Hungary|Israel|Italy|Mexico|Netherlands|Norway|Poland|Portugal|Romania|Russian Federation|South Africa|Spain|Sweden|Ukraine|United Kingdom 1
United States|Argentina|Brazil|Chile|Colombia|Lithuania|Netherlands|Peru|Venezuela 1
United States|Australia|Austria|Belgium|Brazil|Canada|Colombia|Czechia|Finland|Greece|Hungary|Italy|Malaysia|Netherlands|New Zealand|Norway|Poland|Portugal|Russian Federation|Slovenia|South Africa|Spain|Switzerland|Taiwan|Turkey|United Kingdom 1
United States|Australia|Austria|Belgium|Brazil|Canada|Colombia|Czechia|Greece|Hungary|Italy|Malaysia|Netherlands|Norway|Poland|Portugal|Russian Federation|Slovenia|South Africa|Spain|Switzerland|Turkey|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Czechia|Denmark|Hungary|South Africa 1
United States|Australia|Austria|Canada|Czechia|Denmark|France|Israel|Italy|Japan|Jordan|Netherlands|New Zealand|Norway|Poland|Russian Federation|South Africa|Spain|Sweden|United Kingdom 1
United States|Australia|Austria|Canada|Czechia|France|Greece|Italy|Japan|Netherlands|South Africa|Ukraine 1
United States|Australia|Austria|Canada|France|Greece|Italy|Japan|Netherlands|South Africa|Ukraine 1
United States|Australia|Belgium|Canada|Czechia|Denmark|Finland|Germany|Hong Kong|Hungary|Japan|Netherlands|Norway|Singapore|South Africa|Spain|Sweden|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|Denmark|France|Germany|Hong Kong|Hungary|Italy|Korea, Republic of|Mexico|Netherlands|Russian Federation|South Africa|Spain|Sweden|Switzerland|Taiwan|United Kingdom 1
United States|Australia|Belgium|Canada|Denmark|Netherlands|New Zealand|Spain 1
United States|Australia|Canada|Denmark|France|Iceland|Norway|South Africa|Sweden| 1
United States|Australia|Canada|France|Germany|Hong Kong|Netherlands|New Zealand|Norway|South Africa|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Czechia|France|Germany|Italy|Spain|United Kingdom 1
United States|Austria|Belgium|France|Germany|Italy|Netherlands|Spain|Switzerland|United Kingdom 1
United States|Austria|Canada|Czech Republic|Denmark|France|Israel|Netherlands|Norway|Russian Federation|South Africa|Spain|Sweden|United Kingdom 1
United States|Austria|Canada|Czechia|France|Germany|Greece|Italy|Japan|South Africa|Taiwan|Turkey|Ukraine 1
United States|Austria|Canada|France|Israel|Italy|Norway|United Kingdom 1
United States|Belgium|Canada|Czechia|France|Hong Kong|Italy|Lebanon|Netherlands|New Zealand|South Africa|Spain 1
United States|Belgium|Canada|Germany|Greece|Hungary|Italy|Norway|Poland|Puerto Rico|Russian Federation|Slovakia|Spain|Switzerland|Turkey 1
United States|Belgium|Canada|Italy|Mexico|Poland|Spain 1
United States|Belgium|Canada|Netherlands|Norway 1
United States|Belgium|Czech Republic|Finland|France|Germany|Netherlands|Norway 1
United States|Belgium|Finland|Netherlands 1
United States|Bulgaria|Canada|Finland|Italy|Netherlands|Norway|Poland|South Africa|Spain|United Kingdom 1
United States|Bulgaria|Canada|Hungary|Israel|Norway|Slovakia|United Kingdom 1
United States|Canada|Czech Republic|Finland|France|Italy|Netherlands|South Africa 1
United States|Canada|Czech Republic|Germany|South Africa|United Kingdom 1
United States|Canada|Czechia|Denmark|Germany|Hungary|Netherlands|Poland|South Africa|Spain|Sweden|Ukraine|United Kingdom 1
United States|Canada|Czechia|Denmark|Japan|Netherlands|Poland|Puerto Rico 1
United States|Canada|Czechia|Denmark|Netherlands|South Africa|Spain|Sweden 1
United States|Canada|Czechia|France|Netherlands|Norway|Russian Federation|South Africa|Spain|Sweden 1
United States|Canada|Denmark|France|Hungary|Israel|Korea, Republic of|Russian Federation|South Africa|Ukraine 1
United States|Canada|Germany|Netherlands|Poland|United Kingdom 1
United States|Canada|Israel 1
United States|Canada|Italy|Netherlands 1
United States|Canada|Italy|Netherlands|United Kingdom 1
United States|Canada|Netherlands 1
United States|Canada|Netherlands|Norway|Spain 1
United States|Canada|Netherlands|Russian Federation|South Africa 1
United States|Canada|South Africa 1
United States|Colombia|India|Mexico 1
United States|Denmark|Germany|Netherlands|Poland|United Kingdom 1
United States|France 1
United States|Germany 1
United States|Israel|Norway|South Africa|Turkey 1
United States|Netherlands|South Africa 1
United States|Puerto Rico 1
Vietnam 1

Sites per Study

Site_count Study_Count
1 451
2 37
3 13
4 6
5 10
6 9
7 8
8 6
9 7
10 5
11 2
12 3
13 5
14 6
15 1
16 2
17 3
19 1
20 6
21 1
22 1
24 1
25 1
26 3
27 5
28 3
30 3
31 2
32 1
33 1
34 2
35 7
37 2
38 1
39 2
40 1
41 2
42 2
43 1
44 2
45 1
46 1
47 2
48 1
49 2
52 1
53 1
54 1
58 1
59 2
62 3
66 2
67 3
68 1
70 2
72 1
74 2
76 1
78 1
83 1
84 1
88 1
91 1
92 1
93 1
95 1
96 1
97 1
104 1
110 1
116 1
126 3
129 1
133 1
145 1
153 1
168 1
171 1
177 1
186 1
187 1
189 1
192 1
226 1
240 1
244 1
320 1

Phase

Phase Study_Count
Phase 3 223
N/A 169
Phase 2 103
Phase 4 102
Phase 1 61
Phase 1/Phase 2 12
Phase 2/Phase 3 8
Early Phase 1 6

Number of Arms

Number_of_Arms Count_of_Studies
1 75
2 294
3 94
4 50
5 22
6 21
7 4
8 4
9 2
10 2
11 1
12 2
13 1
16 1
24 1
NA 110

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 22.0 6.0000 1.00000 12.0 6.000 30.000 9.0000 8.0000
1st Qu. 78.0 43.0000 25.00000 40.0 40.000 59.500 150.2500 41.0000
Median 78.0 62.0000 40.00000 45.5 66.000 80.000 400.0000 100.0000
Mean 202.6 340.9527 55.08197 60.0 137.505 135.375 841.1636 268.7921
3rd Qu. 130.0 155.0000 69.00000 59.0 157.000 228.750 828.7500 200.0000
Max. 705.0 24000.0000 500.00000 180.0 1324.000 300.000 18144.0000 8000.0000

Trial Group Type

group_type Group_Count
Experimental 845
Active Comparator 368
Placebo Comparator 265
NA 110
Other 55
No Intervention 28
Sham Comparator 6

Intervention Model

intervention_model Study_Count
Parallel Assignment 472
Single Group Assignment 93
Crossover Assignment 81
Factorial Assignment 16
NA 15
Sequential Assignment 7

Primary Purpose

primary_purpose Study_Count
Treatment 504
Prevention 73
Basic Science 44
NA 27
Other 13
Supportive Care 8
Health Services Research 7
Diagnostic 6
Screening 2

Observational Studies

Studies by Country

Country Study_Count
NA 49
United States 23
Canada 6
Italy 6
Korea, Republic of 5
Greece 3
Spain 3
Japan 2
Netherlands 2
Russian Federation 2
Turkey 2
United Arab Emirates 2
Australia|Austria|Belgium|Czechia|Denmark|Greece|Italy|Netherlands|Norway|Slovakia|Spain|Sweden|Switzerland|United Kingdom 1
Austria|Denmark|Finland|France|Germany|Italy|United Kingdom 1
Belgium|Austria|Bulgaria|Czechia|Germany|Greece|Italy|Portugal|Slovakia|Spain|Sweden|Switzerland 1
Bosnia and Herzegovina 1
China 1
China|Indonesia|Korea, Republic of|Malaysia|Philippines|Taiwan|Thailand|Vietnam 1
Croatia 1
Egypt 1
Germany 1
Germany|India|Sri Lanka 1
Portugal 1
Saudi Arabia 1
Serbia 1
Singapore 1
South Africa 1
Sweden 1
Vietnam 1

Sites per Study

Site_count Study_Count
1 96
2 3
3 2
4 1
5 1
6 1
8 2
10 2
11 2
12 1
14 1
27 2
48 1
49 1
59 1
75 1
81 1
139 1
190 1
215 1

Enrollment Metrics

Measure Observational
Min 5.00
1st Qu 237.50
Median 855.00
Mean 1026273.84
3rd Qu 3053.75
Max 99999999.00

Observation Model

observational_model Study_Count
Cohort 46
NA 33
Case-Only 20
Case Control 7
Case-Control 5
Other 5
Defined Population, Natural History 2
Case-Crossover 1
Ecologic or Community 1
Family-Based 1
Natural History 1

Time Perspective

time_perspective Study_Count
Prospective 73
NA 21
Cross-Sectional 14
Retrospective 10
Longitudinal, Prospective 2
Other 2

Registries

Studies by Country

Country Study_Count
United States 4
Iran, Islamic Republic of 2
Belgium 1
Canada 1
China 1
Greece 1
NA 1
Russian Federation 1
United Kingdom 1

Sites per Study

Site_count Study_Count
1 10
5 1
14 1
54 1

Enrollment Metrics

Measure Registries
Min 150.0
1st Qu 500.0
Median 1000.0
Mean 132734.3
3rd Qu 6000.0
Max 1622948.0

Registry Model

observational_model Study_Count
Cohort 11
Other 1
NA 1

Time Perspective

time_perspective Study_Count
Prospective 10
Cross-Sectional 2
NA 1

Follow-up

target_duration Study_Count
5 Years 4
10 Years 3
1 Day 1
1 Month 1
12 Weeks 1
15 Years 1
3 Years 1
6 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT04271280 Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events https://ClinicalTrials.gov/show/NCT04271280 Recruiting Daiichi Sankyo, Inc. 2021-12-31
NCT03379558 Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study https://ClinicalTrials.gov/show/NCT03379558 Active, not recruiting Sanofi 2028-09-30
NCT03394859 Electronic Medical Records and Genomics (eMERGE) Phase III https://ClinicalTrials.gov/show/NCT03394859 Completed Vanderbilt University Medical Center 2020-04-01
NCT03253432 IN-TANDEM Familial Hypercholesterolemia Pilot Study https://ClinicalTrials.gov/show/NCT03253432 Completed University of Pennsylvania 2018-11-07
NCT03198897 Biomarker for Homozygous Familial Hypercholesterolemia (BioHoFH) https://ClinicalTrials.gov/show/NCT03198897 Active, not recruiting Centogene AG Rostock 2021-06-30
NCT03110250 Familial Hypercholesterolemia in Turkey (A-HIT2) https://ClinicalTrials.gov/show/NCT03110250 Completed Ege University 2017-11-30
NCT03018678 Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT03018678 Completed University of Pennsylvania 2017-05-30
NCT02976818 Lp(a) and Aortic Valve Calcification https://ClinicalTrials.gov/show/NCT02976818 Completed Laval University 2019-10-31
NCT02906124 Study to Evaluate the Safety of Repatha® in Pregnancy https://ClinicalTrials.gov/show/NCT02906124 Recruiting Amgen 2026-06-19
NCT02808403 Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan https://ClinicalTrials.gov/show/NCT02808403 Recruiting Amgen 2022-04-30
NCT02770131 Chart Review of Repatha® in Subjects With Hyperlipidaemia https://ClinicalTrials.gov/show/NCT02770131 Recruiting Amgen 2021-06-24
NCT02750527 Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany https://ClinicalTrials.gov/show/NCT02750527 Enrolling by invitation Kinderkrankenhaus auf der Bult 2020-12-31
NCT02721992 Graves’ Orbitopathy and Hypercholesterolemia https://ClinicalTrials.gov/show/NCT02721992 Completed University of Pisa 2017-06-30
NCT02694094 Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy https://ClinicalTrials.gov/show/NCT02694094 Enrolling by invitation Johns Hopkins University 2022-12-31
NCT02693548 The Spanish Familial Hypercholesterolaemia Cohort Study https://ClinicalTrials.gov/show/NCT02693548 Recruiting Fundación Hipercolesterolemia Familiar 2020-10-31
NCT00001154 Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins https://ClinicalTrials.gov/show/NCT00001154 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT02523001 Effect of Statin Treatment on Urinary AQP2 (uAQP2/01) https://ClinicalTrials.gov/show/NCT02523001 Completed University of Bari 2014-05-31
NCT02518516 High Potency Statins and Acute Kidney Injury https://ClinicalTrials.gov/show/NCT02518516 Completed Canadian Network for Observational Drug Effect Studies, CNODES 2013-01-31
NCT02392416 Atorvastatin Study in Cardiovascular Disease Risk https://ClinicalTrials.gov/show/NCT02392416 Completed Elpen Pharmaceutical Co. Inc. 2016-02-29
NCT02286596 Comparisons of Two Low-density Lipoprotein Apheresis Systems in Patients With Homozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT02286596 Completed Laval University 2013-06-30
NCT02230241 CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II) https://ClinicalTrials.gov/show/NCT02230241 Completed AstraZeneca 2015-11-30
NCT02225340 Relationships Between Plasma PCSK9 Levels, LDL-cholesterol Concentrations and Lipoprotein (a) Levels in Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT02225340 Completed Laval University 2014-04-30
NCT01878604 Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT01878604 Completed Central South University 2014-10-31
NCT01768403 Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia https://ClinicalTrials.gov/show/NCT01768403 Completed AstraZeneca 2011-03-31
NCT01753232 Safety and Efficacy of the DALI LDL-adsorber and MONET Lipoprotein Filter https://ClinicalTrials.gov/show/NCT01753232 Completed Fresenius Medical Care Deutschland GmbH 2014-12-31
NCT01678521 Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients https://ClinicalTrials.gov/show/NCT01678521 Completed Universita di Verona 2013-12-31
NCT01625884 Observational Study to Understand Patients’ and Physicians’ Attitudes to Statins in TurkeY https://ClinicalTrials.gov/show/NCT01625884 Completed AstraZeneca 2012-12-31
NCT01614561 An Observational Study Evaluating Cholesterol Levels in Patients on Cholesterol Lowering Drugs in Jordan and Lebanon https://ClinicalTrials.gov/show/NCT01614561 Completed AstraZeneca 2010-12-31
NCT01604733 Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia https://ClinicalTrials.gov/show/NCT01604733 Completed AstraZeneca 2011-06-30
NCT01575171 Using Nudges to Implement Comparative Effectiveness https://ClinicalTrials.gov/show/NCT01575171 Completed NYU Langone Health 2015-05-31
NCT01569867 Genetic Influence on Statin Pharmacokinetics https://ClinicalTrials.gov/show/NCT01569867 Recruiting Ohio State University 2020-06-30
NCT01483950 Evaluation of Patients Treated With HMG-CoA Reductase Inhibitors to Reach Cholesterol Target Values https://ClinicalTrials.gov/show/NCT01483950 Completed AstraZeneca 2013-01-31
NCT01477944 Pattern of Statins Use in Catalonia https://ClinicalTrials.gov/show/NCT01477944 Completed AstraZeneca 2012-02-29
NCT01446679 Special Drug Use-Results Survey of Lipitor Tablets https://ClinicalTrials.gov/show/NCT01446679 Completed Astellas Pharma Inc 2012-03-31
NCT01414192 A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204) https://ClinicalTrials.gov/show/NCT01414192 Completed Merck Sharp & Dohme Corp. 2014-09-15
NCT01381679 Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1) https://ClinicalTrials.gov/show/NCT01381679 Completed Merck Sharp & Dohme Corp. 2010-12-31
NCT01352897 Registry On Efficacy and Safety Of Rosuvastatin, and Atorvastatin and Simvastatin In Hypercholesterolaemia https://ClinicalTrials.gov/show/NCT01352897 Completed AstraZeneca 2010-12-31
NCT04433429 Nutraceuticals and Vascular Remodelling https://ClinicalTrials.gov/show/NCT04433429 Completed University of Padova 2017-12-31
NCT04402112 Efficacy and Safety of Pitavastatin in a Real-world Setting https://ClinicalTrials.gov/show/NCT04402112 Completed JW Pharmaceutical 2017-04-01
NCT04370899 Early Detection of Familial Hypercholesterolemia in Children https://ClinicalTrials.gov/show/NCT04370899 Recruiting Institut Investigacio Sanitaria Pere Virgili 2023-03-14
NCT04319081 Study to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 Inhibitors https://ClinicalTrials.gov/show/NCT04319081 Recruiting Hospital Clinico Universitario de Santiago 2022-05-01
NCT04317690 Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey https://ClinicalTrials.gov/show/NCT04317690 Enrolling by invitation Massachusetts General Hospital 2020-04-30
NCT04313270 Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab® https://ClinicalTrials.gov/show/NCT04313270 Recruiting Federico II University 2022-12-01
NCT04270344 The Occurrence of MACE in Patients With AMI Receiving Pitavastatin/Valsartan Treatment https://ClinicalTrials.gov/show/NCT04270344 Recruiting JW Pharmaceutical 2020-12-31
NCT04148339 A Pilot Study to Explore the Role of Gut Flora in Elevated Cholesterol https://ClinicalTrials.gov/show/NCT04148339 Recruiting ProgenaBiome 2023-03-31
NCT04148001 Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients https://ClinicalTrials.gov/show/NCT04148001 Active, not recruiting Regenxbio Inc. 2020-12-30
NCT04080050 A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501 https://ClinicalTrials.gov/show/NCT04080050 Enrolling by invitation Regenxbio Inc. 2024-09-29
NCT03856476 The Effect of Childhood Dyslipidemia on Endothelial and Renal Function https://ClinicalTrials.gov/show/NCT03856476 Recruiting University of Ioannina 2020-04-03
NCT03640234 Return of Actionable Variants Empirical Study https://ClinicalTrials.gov/show/NCT03640234 Enrolling by invitation Mayo Clinic 2020-06-30
NCT03631238 The Dual Impact of Homocysteine and Cholesterol on Cognitive Functions https://ClinicalTrials.gov/show/NCT03631238 Completed Assiut University 2018-06-01
NCT03597958 Genetic Causes of Hypercholesterolaemia in the Emirati Population https://ClinicalTrials.gov/show/NCT03597958 Recruiting Imperial College London Diabetes Centre 2020-12-31
NCT03520140 Prevalence of Familial Hypercholesterolaemia (FH) in Italian Patients With Coronary Artery Disease https://ClinicalTrials.gov/show/NCT03520140 Completed Heart Care Foundation 2018-05-30
NCT03516955 Efficacy and Safety of a Generic Rosuvastatin in a Real-world Setting https://ClinicalTrials.gov/show/NCT03516955 Completed Hikma Pharmaceuticals LLC 2015-08-31
NCT01257971 Non-interventional Study (NIS) to Assess Reaching of Cholesterol Target Values in Patients Treated With HMG-CoA Reductase Inhibitors https://ClinicalTrials.gov/show/NCT01257971 Completed AstraZeneca 2011-10-31
NCT01245738 Effect of Statins on Lipid Levels Following the First Acute Coronary Event (MK-0000-204) https://ClinicalTrials.gov/show/NCT01245738 Completed Merck Sharp & Dohme Corp. 2012-12-31
NCT01243255 Polish Survey on the Efficacy of the Hypercholesterolemia Treatment https://ClinicalTrials.gov/show/NCT01243255 Completed AstraZeneca 2011-06-30
NCT01242319 Translating ATP III Cholesterol Management Guidelines Into Primary Care Practice https://ClinicalTrials.gov/show/NCT01242319 Completed Memorial Hospital of Rhode Island 2008-08-31
NCT01222182 Statin Interchange by Pharmacist Collaborative Practice Agreement (CPA) https://ClinicalTrials.gov/show/NCT01222182 Completed Mayo Clinic 2011-02-28
NCT01221584 Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia https://ClinicalTrials.gov/show/NCT01221584 Completed AstraZeneca 2011-03-31
NCT01206231 An Epidemiological Study Aimed to Record Standard Daily Practice in Managing Patients With Hypercholesterolemia https://ClinicalTrials.gov/show/NCT01206231 Completed AstraZeneca 2011-10-31
NCT01138371 Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers https://ClinicalTrials.gov/show/NCT01138371 Completed Emory University 2012-02-29
NCT01117831 An Analysis of Diabetes Control in Puerto Rico https://ClinicalTrials.gov/show/NCT01117831 Completed Center for Diabetes Control, Inc. 2012-11-30
NCT01109368 The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository https://ClinicalTrials.gov/show/NCT01109368 Recruiting The Rogosin Institute 2025-05-31
NCT01107743 Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) https://ClinicalTrials.gov/show/NCT01107743 Completed Pfizer 2012-04-30
NCT01070966 Vytorin Reexamination Study (0653A-174) https://ClinicalTrials.gov/show/NCT01070966 Completed Merck Sharp & Dohme Corp. 2010-04-30
NCT01070953 EZETROL® Re-examination Study (MK0653-175)(COMPLETED) https://ClinicalTrials.gov/show/NCT01070953 Completed Merck Sharp & Dohme Corp. 2010-07-31
NCT01031277 Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf States https://ClinicalTrials.gov/show/NCT01031277 Completed AstraZeneca 2010-07-31
NCT01027624 Centralized Pan-South African Survey on the Undertreatment of Hypercholesterolaemia https://ClinicalTrials.gov/show/NCT01027624 Completed AstraZeneca 2010-04-30
NCT01025388 Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia https://ClinicalTrials.gov/show/NCT01025388 Completed AstraZeneca 2010-05-31
NCT01011127 Different Metabolic Effects of Statins https://ClinicalTrials.gov/show/NCT01011127 Completed Gachon University Gil Medical Center 2010-07-31
NCT00909389 Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647) https://ClinicalTrials.gov/show/NCT00909389 Completed Merck Sharp & Dohme Corp. 2008-11-30
NCT00848276 Sex Hormones and Blood PCSK9 Levels https://ClinicalTrials.gov/show/NCT00848276 Completed Ottawa Hospital Research Institute 2010-09-30
NCT00837083 Evaluation of Crestor® (Rosuvastatin) in Daily Practice https://ClinicalTrials.gov/show/NCT00837083 Completed AstraZeneca NA
NCT04101149 Genetic Causes of Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT04101149 Recruiting Region Örebro County 2025-12-31
NCT04133805 The Effect of Viscous Dietary Fibers on LDL-cholesterol https://ClinicalTrials.gov/show/NCT04133805 Active, not recruiting St. Michael’s Hospital, Toronto 2019-12-31
NCT00730132 Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <> (Study P05464) https://ClinicalTrials.gov/show/NCT00730132 Completed Merck Sharp & Dohme Corp. 2009-08-31
NCT00724477 Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED) https://ClinicalTrials.gov/show/NCT00724477 Completed Merck Sharp & Dohme Corp. 2008-08-31
NCT00723723 Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED) https://ClinicalTrials.gov/show/NCT00723723 Completed Merck Sharp & Dohme Corp. 2009-06-30
NCT00705211 A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245) https://ClinicalTrials.gov/show/NCT00705211 Completed Merck Sharp & Dohme Corp. 2009-12-31
NCT00705081 Evaluation of the LDL-C Lowering Effects of Ezetimibe Achieved in Co-administration Therapy With Statins in an Indonesian Population (Study P04276)(COMPLETED) https://ClinicalTrials.gov/show/NCT00705081 Completed Merck Sharp & Dohme Corp. 2007-12-31
NCT00704535 Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED) https://ClinicalTrials.gov/show/NCT00704535 Completed Merck Sharp & Dohme Corp. 2008-04-30
NCT00704444 A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244) https://ClinicalTrials.gov/show/NCT00704444 Completed Merck Sharp & Dohme Corp. 2009-09-30
NCT00695539 Rosuvastatin Efficacy and Safety Evaluation in Hypercholesterolaemic Patients https://ClinicalTrials.gov/show/NCT00695539 Completed AstraZeneca NA
NCT00688454 C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients https://ClinicalTrials.gov/show/NCT00688454 Completed AstraZeneca NA
NCT00687492 Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia https://ClinicalTrials.gov/show/NCT00687492 Completed AstraZeneca 2008-12-31
NCT00660764 Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS) https://ClinicalTrials.gov/show/NCT00660764 Completed AstraZeneca NA
NCT00574782 Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE) https://ClinicalTrials.gov/show/NCT00574782 Completed AstraZeneca NA
NCT00546559 Differential Metabolic Effects of Statins https://ClinicalTrials.gov/show/NCT00546559 Completed Gachon University Gil Medical Center NA
NCT00546182 Simvastatin Reduces Adiponectin Levels and Insulin Sensitivity https://ClinicalTrials.gov/show/NCT00546182 Completed Gachon University Gil Medical Center NA
NCT00542867 Pan-European Survey on the Under Treatment of Hypercholesterolemia https://ClinicalTrials.gov/show/NCT00542867 Completed AstraZeneca NA
NCT00526721 Real-life EValuation Of High Dose RosUvastatin in High Risk Patients After TitraTION https://ClinicalTrials.gov/show/NCT00526721 Completed AstraZeneca 2008-04-30
NCT00523796 InPractice Survey on the Treatment of Hypercholesterolemia https://ClinicalTrials.gov/show/NCT00523796 Completed AstraZeneca 2007-11-30
NCT00388180 An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation https://ClinicalTrials.gov/show/NCT00388180 Completed GlaxoSmithKline NA
NCT00353782 Causes and Natural History of Dyslipidemias https://ClinicalTrials.gov/show/NCT00353782 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT00347217 Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event https://ClinicalTrials.gov/show/NCT00347217 Completed AstraZeneca NA
NCT00240344 Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal https://ClinicalTrials.gov/show/NCT00240344 Completed AstraZeneca 2008-02-29
NCT00115232 Inflammatory Profiles of Children at High Risk for Atherosclerosis https://ClinicalTrials.gov/show/NCT00115232 Completed Boston Children’s Hospital 2006-10-31
NCT00114491 Rosuvastatin Affecting Aortic Valve Endothelium https://ClinicalTrials.gov/show/NCT00114491 Completed Hospital Pedro Hispano NA
NCT00067587 Metabolic Abnormalities in HIV Infected and Uninfected Young Women https://ClinicalTrials.gov/show/NCT00067587 Completed University of North Carolina, Chapel Hill 2005-06-30
NCT00006071 Effects of Rosiglitazone on Blood Vessels in Patients With High Blood Pressure and High Cholesterol https://ClinicalTrials.gov/show/NCT00006071 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001742 The Role of Cyclooxygenase Activity in the Endothelial Function of Hypertensive and Hypercholesterolemic Patients https://ClinicalTrials.gov/show/NCT00001742 Completed National Institutes of Health Clinical Center (CC) NA
NCT00037401 Postprandial Lipemia and Endothelial Function in ACCORD- Ancillary to ACCORD https://ClinicalTrials.gov/show/NCT00037401 Completed National Heart, Lung, and Blood Institute (NHLBI) 2005-08-31
NCT00396110 Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET) https://ClinicalTrials.gov/show/NCT00396110 Completed AstraZeneca NA
NCT00005718 Evaluation of Cholesterol Education for At-Risk Children https://ClinicalTrials.gov/show/NCT00005718 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00005694 Worksites, Occupational Nurses and Cholesterol Change https://ClinicalTrials.gov/show/NCT00005694 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00005495 Primary Prevention of CHD Risk Factors Occurring in US https://ClinicalTrials.gov/show/NCT00005495 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00005478 Precursors of CVD Risk Factors–Project Heartbeat https://ClinicalTrials.gov/show/NCT00005478 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00005468 Lipid Variability–Influence of Stress https://ClinicalTrials.gov/show/NCT00005468 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00005463 Population-Based Modeling of Cholesterol Lowering in the United States https://ClinicalTrials.gov/show/NCT00005463 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00005439 Evaluation of Childhood Blood Pressure and Lipid Screening https://ClinicalTrials.gov/show/NCT00005439 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00005350 Evaluating Strategies to Control Hypercholesterolemia https://ClinicalTrials.gov/show/NCT00005350 Completed National Bureau of Economic Research, Inc. NA
NCT00005336 Dietary Treatment of Hyperlipidemia in Women vs. Men https://ClinicalTrials.gov/show/NCT00005336 Completed University of Washington NA
NCT00005313 Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia https://ClinicalTrials.gov/show/NCT00005313 Completed University of Washington 2003-03-31
NCT00005257 Diet and Plasma Cholesterol - Secular Trend Analysis https://ClinicalTrials.gov/show/NCT00005257 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00005210 Sex Steroids, Obesity and Lipids in Adolescent Females https://ClinicalTrials.gov/show/NCT00005210 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00005203 Genetics of Low Density Lipoprotein Subclasses in Hypercholesterolemia https://ClinicalTrials.gov/show/NCT00005203 Completed University of Washington NA
NCT00005178 Study of Children’s Activity and Nutrition (SCAN) https://ClinicalTrials.gov/show/NCT00005178 Completed Augusta University NA
NCT00005168 Hyperapo B and Coronary Heart Disease https://ClinicalTrials.gov/show/NCT00005168 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00005151 Pawtucket Heart Health Program https://ClinicalTrials.gov/show/NCT00005151 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00005134 Strong Heart Study https://ClinicalTrials.gov/show/NCT00005134 Completed National Heart, Lung, and Blood Institute (NHLBI) 2005-12-31
NCT00001204 Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers https://ClinicalTrials.gov/show/NCT00001204 Active, not recruiting National Institutes of Health Clinical Center (CC) NA
NCT00004481 Genetic Study of Sitosterolemia https://ClinicalTrials.gov/show/NCT00004481 Completed National Center for Research Resources (NCRR) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03140605 Greek Registry - Familial Hypercholesterolaemia https://ClinicalTrials.gov/show/NCT03140605 Recruiting Hellenic College of Treatment of Atherosclerosis 2020-04-10
NCT02957604 Evolocumab Pregnancy Exposure Registry https://ClinicalTrials.gov/show/NCT02957604 Recruiting Amgen 2032-04-28
NCT02870660 Familial Hypercholesterolemia Amongst Patients With Acute Coronary Syndrome https://ClinicalTrials.gov/show/NCT02870660 Recruiting Isfahan University of Medical Sciences 2018-09-30
NCT02865694 Developing and Implementing Familial Hypercholesterolemia Registry https://ClinicalTrials.gov/show/NCT02865694 Recruiting Isfahan University of Medical Sciences 2017-09-30
NCT02778646 Detection of Familial Hypercholesterolaemia in Cardiovascular Disease Registry https://ClinicalTrials.gov/show/NCT02778646 Completed University College, London 2014-12-31
NCT02565615 Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting https://ClinicalTrials.gov/show/NCT02565615 Completed Pfizer 2018-08-31
NCT02341664 Patient and Provider Assessment of Lipid Management Registry https://ClinicalTrials.gov/show/NCT02341664 Completed Duke University 2016-02-29
NCT02208869 Russian Familial Hypercholesterolemia Registry https://ClinicalTrials.gov/show/NCT02208869 Recruiting Russian Cardiology Research and Production Center 2017-12-31
NCT02009345 Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada https://ClinicalTrials.gov/show/NCT02009345 Recruiting McGill University Health Centre/Research Institute of the McGill University Health Centre 2016-11-30
NCT01960244 Study of Awareness and Detection of Familial Hypercholesterolemia https://ClinicalTrials.gov/show/NCT01960244 Recruiting The Familial Hypercholesterolemia Foundation 2020-12-31
NCT01867203 Functional and Clinical Impact of CYP3A Genetic Polymorphisms on Statin Therapy https://ClinicalTrials.gov/show/NCT01867203 Recruiting Cliniques universitaires Saint-Luc- Université Catholique de Louvain 2019-08-31
NCT04272697 EAS Familial Hypercholesterolaemia Studies Collaboration https://ClinicalTrials.gov/show/NCT04272697 Recruiting Imperial College London 2025-12-31
NCT02135705 LOWER: Lomitapide Observational Worldwide Evaluation Registry https://ClinicalTrials.gov/show/NCT02135705 Enrolling by invitation Aegerion Pharmaceuticals, Inc. 2028-03-31